Loading…
Loading…
Hope Bancorp is rated Buy, trading below book value and at a 43% discount to the financial sector despite a forward ROE 5.6x higher than the sector median. The MANUBANK acquisition is expected to drive near-term earnings growth, with management guiding for 20% loan and 15–20% revenue growth in FY26. NIM expansion, robust CET1 ratio (12.3%), and stable asset quality support a 4.2% yield and ongoing share repurchases.
LOS ANGELES--(BUSINESS WIRE)--Hope Bancorp, Inc. (“the Company”) (NASDAQ: HOPE) today announced that the Company will report financial results for its third quarter and nine months ended September 30, 2026, before the markets open on Wednesday, October 28, 2026. A conference call to discuss financial results for the third quarter and nine months ended September 30, 2026, will be held on Wednesday, October 28, 2026, at 9:30 a.m. Pacific Time / 12:30 p.m. Eastern Time. A presentation deck to acco.
Hope Bancorp (HOPE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Hope Bancorp, Inc. (NASDAQ: HOPE - Get Free Report)'s share price crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $13.06 and traded as high as $13.75. Hope Bancorp shares last traded at $13.57, with a volume of 1,048,202 shares traded. Wall Street Analyst Weigh In Several
-24-Month Crossover Analysis: Patients Starting Deramiocel After a Year on Placebo Slowed Upper Limb Decline by 76% Compared with Their Own Prior Year- -At 24 Months, Both Groups Showed Slower Decline in Upper Limb Function Than Natural History Predicts- -Data Included in Deramiocel BLA Major Amendment; PDUFA Target Action Date November 22, 2026- -Webinar Scheduled for October 7, 2026, at 1:00 p.m. ET in Collaboration with PPMD to Discuss the Data- SAN DIEGO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced positive new data from its ongoing HOPE-3 open-label extension (OLE) study for its lead asset, Deramiocel, for the treatment of upper limb impairment in Duchenne muscular dystrophy (DMD).
LOS ANGELES--(BUSINESS WIRE)--Hope Bancorp, Inc. (NASDAQ: HOPE) today announced that its wholly-owned subsidiary, Bank of Hope (“the Bank”), has completed its previously announced acquisition of the Commercial Banking Unit of SMBC MANUBANK (“MANUBANK”), a wholly-owned subsidiary of SMBC Americas Holdings, Inc. and Sumitomo Mitsui Banking Corporation (“SMBC”). The acquisition adds an established commercial banking franchise and seasoned professionals to Bank of Hope, diversifying its deposit seg.
– Late-Breaking Data to Include HOPE-3 Delayed-Start and Natural History Analyses Submitted in the Recent Major Amendment to the Deramiocel BLA – – PDUFA Target Action Date of November 22, 2026 – SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that data from HOPE-3 and its open-label extension (OLE) of Deramiocel, the Company's lead asset for the treatment of Duchenne muscular dystrophy (DMD), will be presented in a late-breaking poster and an oral presentation at the 31 st Annual Congress of the World Muscle Society (WMS 2026), taking place September 29 – October 3, 2026, in Hiroshima, Japan.
LOS ANGELES--(BUSINESS WIRE)--Hope Bancorp, Inc. (NASDAQ: HOPE) today announced that its wholly-owned subsidiary, Bank of Hope, has received all regulatory approvals required to complete the previously announced acquisition of the Commercial Banking Unit of SMBC MANUBANK (“MANUBANK”), a wholly owned subsidiary of SMBC Americas Holdings, Inc. and Sumitomo Mitsui Banking Corporation (“SMBC”). Regulatory approvals have been received from the Federal Deposit Insurance Corporation and the California.